Sechenov School
Home › Pharmacology › Ambroxol

Ambroxol

Ambroxolum

For medical students2 min readUpdated 2026-10-10

Ambroxol is an effective expectorant drug with prominent mucolytic and mucokinetic activity. It not only liquefies viscous mucus, but also actively stimulates pulmonary surfactant production, significantly facilitating breathing in various respiratory tract disorders.

Onset of actionThe therapeutic effect develops within 30 minutes after oral administration.
SurfactantActively stimulates the production and simultaneously decreases the degradation of endogenous surfactant.
StructureIt is a benzylamine derivative, containing bromine atoms and a cyclohexyl ring.
Side effectsMost commonly manifested in the gastrointestinal tract: nausea, vomiting, and intestinal disorders may occur.

Pharmacodynamics: Mechanism of Action

To understand how the drug works, it is necessary to examine its effect on bronchial secretions in detail. Ambroxolum has a complex effect on the respiratory system, consisting of several key components:

Effect on the Pulmonary Surfactant System

One of the most important pharmacological features of the drug is its interaction with endogenous surfactant, a specialized surface-active agent that lines the alveoli and prevents their collapse.

The mechanism of action in this aspect is bidirectional:

  1. Stimulation of production: The drug activates the synthesis of new surfactant in the lungs.
  2. Reduction of degradation: The drug inhibits the degradation processes of existing surfactant.

Due to this property, the drug has found specific application in pediatrics and neonatology. It is prescribed to premature and newborn infants to treat respiratory distress syndrome, which is characterized by a critical shortage of endogenous surfactant.

Chemical Structure and Relation to Other Drugs

When studying the chemical structure of expectorants, it is important to understand their classification. Unlike acetylcysteine, which is a derivative of the amino acid cysteine and exerts its effect through a free sulfhydryl (SH) group, ambroxol has a completely different chemical nature.

Ambroxol and its pharmacological precursor bromhexine share a similar chemical structure. Both compounds belong to the group of benzylamine derivatives. Their molecular structure contains specific bromine atoms, as well as a characteristic cyclohexyl ring. This structural similarity underlies their close pharmacological relationship.

Pharmacokinetics, Indications, and Side Effects

The drug is intended for oral administration. After ingestion, the onset of the therapeutic effect is registered within 30 minutes. The duration of the clinical effect remains high for 10–12 hours.

Indications for use include a wide range of acute and chronic respiratory diseases:

Despite high efficacy, therapy may be accompanied by adverse reactions. Side effects are primarily localized to the gastrointestinal tract. Patients may complain of nausea, episodes of vomiting, and various intestinal disorders.

Mnemonic

To easily remember the mechanism of action, use the rule of three "S"s: Structure (alters mucopolysaccharide structure of sputum), Secretion (increases glycoprotein production), and Surfactant (stimulates its synthesis and inhibits degradation).

Frequently asked questions

What respiratory diseases are indications for ambroxol?

Indications for ambroxol include acute and chronic respiratory diseases, such as:

  • Acute and chronic bronchitis
  • Pneumonia (including community-acquired)
  • Bronchial asthma with difficult sputum expectoration
  • Bronchiectasis
  • COPD during exacerbations with productive cough
  • Respiratory distress syndrome in newborns and premature infants to stimulate surfactant synthesis
What side effects does ambroxol cause?

Side effects of ambroxol mainly manifest in the gastrointestinal tract:

  • Nausea
  • Vomiting
  • Intestinal disorders
What are the contraindications for prescribing ambroxol?

Contraindications for prescribing ambroxol include:

  • Pregnancy, especially the first trimester
  • Breastfeeding
  • Combination with antitussives during a wet cough with bronchial obstruction
What are the main pharmacokinetic parameters of ambroxol?

The main pharmacokinetic parameters of ambroxol include characteristics of administration, onset speed, and duration of the therapeutic effect:

  • Route of administration — oral (per os)
  • Onset of action — therapeutic effect develops 30 minutes after intake
  • Duration of effect — mucolytic action persists for 10–12 hours
What is the principal difference in chemical structure between ambroxol and acetylcysteine?

Acetylcysteine is a derivative of the amino acid cysteine and contains a sulfhydryl (SH) group. Ambroxol, on the other hand, is a benzylamine derivative containing bromine atoms and a cyclohexyl ring in its structure.

How does the drug affect mucociliary clearance?

The drug directly stimulates the motor activity of the ciliated bronchial epithelium, helping cilia transport the liquefied secretion outward more rapidly.

Why is ambroxol a drug of choice in neonatology for respiratory distress syndrome?

This is due to its unique ability to affect endogenous surfactant: the drug stimulates its production in the lungs of premature newborns while simultaneously reducing its breakdown.

How quickly does the effect occur after drug administration and how long does it last?

When taken orally, the effect begins after 30 minutes, and the therapeutic effect persists for 10–12 hours.

Go deeper

More topics in Pharmacology

Vitamin B1CyclosporineCarbonic Anhydrase InhibitorsIndomethacinN-CholinomimeticsCalcium Channel BlockersDopamine Receptor AgonistsIsoprenalineThioxanthene DerivativesMoxonidineClass IC Antiarrhythmic Drugs: Mechanism and Clinical UseGanciclovirPharmacology →